Windtree Therapeutics Inc

NASDAQ: WINT    
Share price (5/10/24): $4.10    
Market cap (5/10/24): $37.7 million
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.61
from 10-K 71 pages License, Development and Commercialization Agreement by and Between Windtree Therapeutics, Inc. and Lee’s Pharmaceutical (Hk) Ltd
12/34/56
EX-10.5
from 10-K 6 pages Amendment No. 1 to the License Agreement
12/34/56
EX-10.3
from 10-K 6 pages Amendment No. 1 to Amended and Restated License Agreement
12/34/56
EX-10.2
from 8-K 27 pages Registration Rights Agreement
12/34/56
EX-10.1
from 8-K 55 pages Securities Purchase Agreement
12/34/56
EX-10.2
from 8-K 9 pages Registration Rights Agreement
12/34/56
EX-10.1
from 8-K 19 pages Exchange and Termination Agreement
12/34/56
EX-10.1
from 8-K 12 pages Amended and Restated Windtree Therapeutics, Inc. 2020 Equity Incentive Plan
12/34/56
EX-10.29
from 10-K 4 pages Third Amendment to Lease Agreement
12/34/56
EX-10.1
from 8-K 11 pages February 21, 2023 [Name and Address of Warrant Holder] Re: Reprice and Reload Offer of Common Stock Purchase Warrants to Whom It May Concern
12/34/56
EX-10.1
from 8-K 11 pages January 20, 2023 [Name and Address of Warrant Holder] Re: Reprice and Reload Offer of Common Stock Purchase Warrants to Whom It May Concern
12/34/56
EX-10.1
from 10-Q 57 pages Amended and Restated License, Development and Commercialization Agreement by and Among Windtree Therapeutics, Inc., Lee’s Pharmaceutical (Hk) Ltd. and Zhaoke Pharmaceutical (Hefei) Co. Ltd
12/34/56
EX-10.54
from 10-K 13 pages Employment Agreement
12/34/56
EX-10.1
from 10-Q 15 pages Agreement for Scientific Collaboration Between
12/34/56
EX-10.1
from 8-K 15 pages Windtree Therapeutics, Inc. 2020 Equity Incentive Plan
12/34/56
EX-10.4
from 10-Q 20 pages Certain Confidential Information Contained in This Document, Marked by [***] Has Been Omitted Because It Is Not Material and Would Likely Cause Competitive Harm to the Registrant if Publicly Disclosed. Project Financing Agreement
12/34/56
EX-10.3
from 10-Q 39 pages Certain Confidential Information Contained in This Document, Marked by [***] Has Been Omitted Because It Is Not Material and Would Likely Cause Competitive Harm to the Registrant if Publicly Disclosed
12/34/56
EX-10.2
from 10-Q 20 pages Certain Confidential Information Contained in This Document, Marked by [***] Has Been Omitted Because It Is Not Material and Would Likely Cause Competitive Harm to the Registrant if Publicly Disclosed. Amended and Restated Supply Agreement
12/34/56
EX-10.1
from 10-Q 27 pages Certain Confidential Information Contained in This Document, Marked by [***] Has Been Omitted Because It Is Not Material and Would Likely Cause Competitive Harm to the Registrant if Publicly Disclosed. Collaboration Agreement Between Discovery Laboratories, Inc., and Battelle Memorial Institute Regarding Development of Aerosurf® Dated as of October 10, 2014 Certain Confidential Information Contained in This Document, Marked by [***] Has Been Omitted Because It Is Not Material and Would Likely Cause Competitive Harm to the Registrant if Publicly Disclosed
12/34/56
EX-10.3
from 10-Q 8 pages Separation and Release Agreement
12/34/56